| Literature DB >> 2673463 |
J A Russell1, P J Selby, B A Ruether, E K Mbidde, S Ashley, G Zulian, J Berry, B Houwen, A R Jones, M C Poon.
Abstract
Twenty patients with Hodgkin's disease which had relapsed at least once after chemotherapy, were treated with melphalan 140-220 mg/m2 i.v. followed by reinfusion of non-cryopreserved autologous bone marrow. Four patients (20%) remain alive and disease-free 28, 45, 52, and 96 months after treatment respectively. There were no treatment-related deaths. This appears to be the only reported series of patients treated with a single agent in this situation. The results are comparable to those achieved by multi-agent regimens with autologous or allogeneic bone marrow transplantation.Entities:
Mesh：
Substances：
Year: 1989 PMID： 2673463
Source DB: PubMed Journal: Bone Marrow Transplant ISSN： 0268-3369 Impact factor: 5.483